NextGen Bioscience, Inc. is a biotechnology company focused on creating a new generation of targeted human therapeutics which are safe and effective against a broad range of cancers and infectious diseases. Headquartered in London, NextGen’s business model is to acquire promising new patented technologies in the fields of cancer and infectious disease, to add significant value to these by advancing them through toxicological assessment or Phase I clinical trials and then outlicensing the technology to a larger partner who has the necessary infrastructure to take the products to market. Headquartered in London, revenues generated from licensing activities will be reinvested in research and development to benefit patients, partners and the Company’s investors.
Management I
NextGen’s World-class Management Team and Scientific Advisory Board directs product development and comprise a seasoned team of esteemed scientists and leading entrepreneurs, each with specialist experience in this field.
Board of Directors
David Cooper is Chairman of NextGen’s Board of Directors. For over 30 years David has led David Cooper Associates as an independent business development practice, helping clients achieve commercial advantage from technology based new business development programmes. He has advised clients in identifying opportunities to add value, optimize the allocation of resources, and how to drive the implementation process. DCA sits upon a deep experience of providing flexible strategies based upon well researched advice and creative problem solving in the high risk activity and complexity, and volatile economic climate of the technology based global business market.
Konstantinos Kardiasmenos, NextGen’s Managing Director and CEO holds a Bachelor (with Honors) Degree in Economics from the University of Essex, England and a DEUG (Higher Diploma) in Economics from University of Sorbonne, Paris. He has passed the English FSA Exam for Futures and Options Representative. At Titan Capital Management Ltd. (a fund management company in London) he held the position of Investment Manager and specialized in structured finance until 2001. Konstantinos engineered financial products, which included mutual funds for the Greek market and risk management models. Konstantinos was responsible for raising a total of $7 million in equity for Kotsovolos (largest electric retailer in Greece) and a cosmetics company in London. At PMG SA (Athens based venture capital company) he was Risk Manager until 2004, advising the board of investment opportunities, which brought incremental profits of $5 million over two years. He currently has his own independent financial advisory firm, which advises the biotech, shipping, construction and retail industries.
Following a law degree at Cambridge University, Graham May’s over 28 years’ experience as a qualified lawyer has made him conversant with all areas of law.Graham’s international experience included 7 years practicing as an attorney-at-law in the Cayman Islands in the areas of banking, insurance, trusts and mutual funds. Since 1989 he has acted as a lawyer and manager in the U.K. financial services industry, first with currency fund managers, Gaiacorp U.K., and then as Managing Director of that group’s London subsidiary, renamed Titan Capital Management, where he was instrumental in developing the worldwide investment management business. Graham jointly established Millers Associates advising plc’s and private companies in all aspects of accounting and corporate/company secretarial procedures. He is also currently a practicing consultant solicitor with City- based Paul Roberts Solicitors. In his role as Chief Operating Officer for the Company he will be operating the London representative office from his own consultancy offices in the City, coordinating the administrative activities of the Company and liaising with the retained executives and consultants.
Dr Karen Jervis, PhD MBA, has held various positions at the Viragen Group, including as Managing Director of Viragen (Scotland) Ltd, Pentlands Science Park, Penicuik, Midlothian and Head of Business Development. At Viragen Dr. Jervis established the Group’s new technology portfolio and programme teams and provided successful leadership of the Group’s Commercialization Strategy. She directed out-licensing of the Group’s lead product in Europe and Australia/New Zealand, securing millions in research funding to support R&D programmes. Dr. Jervis directed establishment and management of the Company Intellectual Property strategy, policies, training programmes and portfolio.Karen has been a lecturer and serves as a visiting Lecturer on biotechnology at the University of Nottingham. Karen is an active volunteer for the Royal Zoological Society in Edinburgh and fundraiser for several charities, including The World Wildlife Fund.
Scientific Advisory Board
Dr. Rolf Witte joined NextGen’s Scientific Advisory Board in January from an illustrious career in investing in new biotechnologies. Dr. Witte is Founder, Partner and CEO of fundamenta CAPITAL AG based in Leverkusen Germany. fundamenta is a hands-on investment fund focused in the Biotech, Pharma, Medical Device and new technology sectors. Dr. Witte is also Chief Financial Officer of CMI GmbH, and has served as CEO of Pegasus Beteiligungen AG, a publicly traded investment fund. He has worked as a lawyer specializing in audit and tax advice and has an academic background drawing degrees in Economics and Law, Dipl. Kfm (MBA). and Ass. iur., as well as a Ph.D. in tax law from the University of Goettingen. and a fellowship for studies in VAT harmonization at the European Commission in Brussels. Dr. Witte has a thorough knowledge of the public funding in Germany and has been successful in raising over $200 million for a number of biotech companies.
Among the other members of the SAB are:
Anders Boegh Jensen, a Denmark biochemist, specializes in biotechnology, genetics and molecular biology. He has served as the head of Poalis A/S agro division. Poalis is a plant based Biotech Company specializing on methods and technologies for high yield biological production of new or known active chemical compounds, and on crops with improved nutritional agronomical traits. Currently, Anders is the Director of Science at the Company. With a long-standing scientific expertise in the field of biotechnology, genetics and molecular biology, he has numeral publications in leading journals including Cell. Anders has served as an Associate Professor at the Institute of Molecular Biology at the University of Copenhagen and currently serves as Chair of the SAB.
After training as a biochemist and meritous service at the Universities of Dundee and Glasgow, Professor William Stimson founded the Division of Immunology at the Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde where he has served as chair since 1981. Professor Stimson was holder of the 1982 City of Glasgow ‘Loving Cup’ and is the Chairman of the Institute of Nanotechnology and the Nanomedicine Committee. He has been intimately involved in the formation of 8 companies and presently sits on the Boards of five. He has supervised 35 PhD and 7 MPhil students. Professor Stimson has published more than 200 scientific papers and 12 patents. He has been Intimately involved in the formation of 8 university ‘spin-out’ companies and consultant to 5 multinationals on a long term basis (incl. Akzo Nobel – 19 years, Rhone Poulenc – 13 years). He has been a director of Viragen. Collaborative work with the Oncology departments at the University of Nottingham and the Memorial Sloan Kettering Cancer Center, New York, has lead to the fruitful production of 2 therapeutic antibodies.
Dr. Wang Chong, a physician with over 19 years [of experience[ in the healthcare industry, practices an expertise in raising capital for and listing small to medium-sized companies. Dr. Chong has served as CFO and Commercial Director of Phytopharm plc, CEO of Osmetech plc, Life Sciences Analyst at Canaccord Capital (Europe) Ltd, and Leader of UK Healthcare Initiatives at premier management consultants Arthur D. Little Inc among other commercial roles. Dr Chong has a medical degree from King’s College London and a MBA from London Business School and serves as a Council Member of the Royal Society of Medicine’s Pharmaceutical Medicine & Research Section and an Associate of the Securities and Investment Institute.
John Savin, B.Sc., Ph.D., MBA has been CEO/founder of Physiomics, a systems biology company and Director in pharmaceutical and biotech industries fpr Gerrard Group investment bank. Savin became a top-10-ranked City analyst working with corporate finance on venture capital, many IPOs, secondary fund raisings, restructuring and due diligence. As a Senior Consultant, John has worked with government and many major corporations. He has served as International Product Manager for Pharmacia Biotech (Sweden) and Amersham International. He carries an active portfolio of projects including interim management, spin out and start up planning and implementation, business development such as product in-licensing, M&A and funding advice and project management in inflammatory disease, cancer and diagnostics, and also writes investment research on listed biotechnology and medical devices companies.
NXBD product development is guided by a team of well known industry leaders serving as the company’s Management Team and Scientific Advisory Board. This world class team of esteemed scientists and entrepreneur leaders each come with specialist experience in biotechnologies.
Management II
NXBD product development is guided by a world class Management Team and Scientific Advisory Board. Each of the esteemed scientists and entrepreneur leaders have specialist experience and are well regarded industry leaders in biotechnologies.
Board of Directors
David Cooper is Chairman of NextGen’s Board of Directors and brings over 30 years experience helping clients achieve commercial advantage from technology through David Cooper Associates, an independent business development practice. By advising clients in identifying value opportunities, optimizing resources, and driving the implementation process. DCA sits upon a broad and rich experience of providing flexible strategies for new business development programmes in the high risk activity and volatile economic climate and complexity of the technology based global business market.
Konstantinos Kardiasmenos, NextGen’s Managing Director has held positions in investment manager and structured financing. Konstantinos engineered financial product and mutual funds for the Greek market and risk management models, raising $7 Million in equity for Kotsovolos (largest electric retailer in Greece) and a cosmetics company in London, At he was Risk Manager until 2004, advising the PMG SA (Athens based venture capital company)board of investment opportunities resulting in $5 million profit over two years. He currently has his own independent financial advisory firm, which advises the biotech, shipping, construction and retail industries.
Cambridge educated Graham May brings 28 years’ experience as a qualified lawyer conversant with all areas of law to NXBG as Chief Operating Officer. Graham practiced 7 years as an attorney-at-law in the Cayman Islands in banking, insurance, trusts and mutual funds. Since 1989 he has acted as a lawyer and manager in the U.K. financial services industry. Graham jointly established Millers Associates advising plc’s and private companies in all aspects of accounting and corporate/company secretarial procedures. As NXBG CEO he will be operating the London representative office from his own consultancy offices in the City, coordinating the administrative activities of the Company and liaising with the retained executives and consultants.
Dr Karen Jervis, PhD MBA, has held various positions, including Managing Director and Head of Business Development, at the Viragen Group, an industry respected biotechnology research company. Dr. Jervis lead the Group’s new technology portfolio and programme teams. She directed the Company Intellectual Property strategy and also out-licensing of the Group’s lead product in Europe and Australia/New Zealand Karen secured millions in research funding to support R&D programmes. She serves as a visiting Lecturer on biotechnology at the University of Nottingham and is an active volunteer for the Royal Zoological Society in Edinburgh and fundraiser for several charities, including The World Wildlife Fund.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC has been compensated 37,000 shares from a non-controlling third party for profile coverage. Pentony Enterprises LLC is not a registered investment adviser or broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this. Pentony Enterprises currently holds no shares.
